Original paper
NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells
Abstract
Prostate cancer is the second leading cause of cancer death among men in the United States. The androgen receptor (AR) antagonist enzalutamide is a Food and Drug Administration–approved drug for treatment of patients with late-stage prostate cancer and is currently under clinical study for early-stage prostate cancer treatment. After a short positive response period, tumors will develop drug resistance. In this study using RNA-Seq and...
Paper Details
Title
NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells
Published Date
May 1, 2019
Volume
294
Issue
21
Pages
8543 - 8554
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History